230 related articles for article (PubMed ID: 28038978)
1. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
[TBL] [Abstract][Full Text] [Related]
2. New limits proposed for the management of non-mutagenic impurities.
Slikkerveer A; Doehr O; Claude N; Hutchinson R; Harvey J; Spanhaak S
Regul Toxicol Pharmacol; 2024 Jun; 150():105647. PubMed ID: 38777301
[TBL] [Abstract][Full Text] [Related]
3. Deriving acceptable limits for non-mutagenic impurities in medicinal products - Durational adjustments.
Kenyon MO; Martin M; Martin EA; Brandstetter S; Wegesser T; Greene N; Harvey J
Regul Toxicol Pharmacol; 2024 Jun; 150():105644. PubMed ID: 38761968
[TBL] [Abstract][Full Text] [Related]
4. Analysis of non-mutagenic substances in the context of drug impurity assessment - Few are potent toxicants.
Hasselgren C; Kenyon M; Anger LT; Cornwell P; Watt E; Bercu J
Regul Toxicol Pharmacol; 2024 Jun; 150():105645. PubMed ID: 38761967
[TBL] [Abstract][Full Text] [Related]
5. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
[TBL] [Abstract][Full Text] [Related]
6. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
Kovarich S; Cappelli CI
Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
[TBL] [Abstract][Full Text] [Related]
7. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
8. Qualification of impurities based on metabolite data.
Weidolf L; Andersson T; Bercu JP; Brink A; Glowienke S; Harvey J; Hayes MA; Jacques P; Lu C; Manevski N; Muster W; Nudelman R; Ogilvie R; Ottosson J; Teasdale A; Trela B
Regul Toxicol Pharmacol; 2020 Feb; 110():104524. PubMed ID: 31734179
[TBL] [Abstract][Full Text] [Related]
9. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
Jenke D; Carlson T
PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
[TBL] [Abstract][Full Text] [Related]
10. Non-mutagenic impurities - Recent industry experience of using dose durational limits in drug development.
Lortie A; Martin EA; Arnot K
Regul Toxicol Pharmacol; 2024 Feb; 147():105559. PubMed ID: 38145838
[TBL] [Abstract][Full Text] [Related]
11. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
[TBL] [Abstract][Full Text] [Related]
12. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Pokar D; Rajput N; Sengupta P
Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
14. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
15. Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates.
Gong HH; Ihle N; Jones MT; Kelly K; Kott L; Raglione T; Whitlock S; Zhang Q; Zheng J
AAPS PharmSciTech; 2018 Apr; 19(3):971-977. PubMed ID: 29302872
[TBL] [Abstract][Full Text] [Related]
16. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
17. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses.
Amberg A; Beilke L; Bercu J; Bower D; Brigo A; Cross KP; Custer L; Dobo K; Dowdy E; Ford KA; Glowienke S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Nicolette J; Plaper A; Powley M; Quigley DP; Reddy MV; Spirkl HP; Stavitskaya L; Teasdale A; Weiner S; Welch DS; White A; Wichard J; Myatt GJ
Regul Toxicol Pharmacol; 2016 Jun; 77():13-24. PubMed ID: 26877192
[TBL] [Abstract][Full Text] [Related]
18. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
Müller L; Gocke E
Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
[TBL] [Abstract][Full Text] [Related]
19. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
